Fresenius Medical Care AG & Co. KGaA (FME) Stock Forecast & Price Target

Compare

18 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

FME Analyst Ratings

Hold

4 Buy

4 Hold

5 Sell

Based on 13 analysts giving stock ratings to

Fresenius

Medical Care AG & Co. KGaA

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

FME Stock 12 Month Forecast

Average Price Target

€46.08

▲(24.64% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Fresenius Medical Care AG & Co. KGaA in the last 3 months. The average price target is €46.08 with a high forecast of €60.00 and a low forecast of €35.00. The average price target represents a 24.64% change from the last price of €36.97.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"34":"€34","61":"€61","40.75":"€40.8","47.5":"€47.5","54.25":"€54.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":46.08,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€46.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€35.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[34,40.75,47.5,54.25,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.76,42.239999999999995,43.72,45.199999999999996,46.68,48.16,49.64,51.12,52.6,54.08,55.56,57.04,58.519999999999996,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.76,41.169230769230765,41.57846153846154,41.987692307692306,42.39692307692307,42.80615384615385,43.215384615384615,43.62461538461538,44.03384615384615,44.44307692307692,44.85230769230769,45.26153846153846,45.67076923076923,{"y":46.08,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.76,40.316923076923075,39.87384615384615,39.43076923076923,38.987692307692306,38.54461538461538,38.10153846153846,37.65846153846154,37.215384615384615,36.77230769230769,36.32923076923077,35.886153846153846,35.44307692307692,{"y":35,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":42.948,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":46.721,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":45.126,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":44.621,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":43.288,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":50.4,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":48.8,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":43.28,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":44.04,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":45.28,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":46.56,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":40.71,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":40.76,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€60.00

Average Price Target€46.08

Lowest Price Target€35.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Graham Doyle

UBS

Sell

―

Reiterated

01/14/26

UBS Reaffirms Their Sell Rating on Fresenius Medical Care AG & Co. KGaA (0H9X)

David Adlington

J.P. Morgan

€37.4

Sell

1.16%

Upside

Reiterated

01/14/26

J.P. Morgan Keeps Their Sell Rating on Fresenius Medical Care AG & Co. KGaA (0H9X)

Oliver Reinberg

Kepler Capital

€49

Hold

32.54%

Upside

Reiterated

01/13/26

Kepler Capital Sticks to Its Hold Rating for Fresenius Medical Care AG & Co. KGaA (0H9X)

Harald Hof

mwb research

€46→€47

Buy

27.13%

Upside

Upgraded

01/12/26

Aisyah Noor

Morgan Stanley

€39→€37

Sell

0.08%

Upside

Reiterated

12/15/25

Fresenius Medical price target lowered to EUR 37 from EUR 39 at Morgan StanleyFresenius Medical price target lowered to EUR 37 from EUR 39 at Morgan Stanley

Anna Ractliffe

Bank of America Securities

€38→€35

Sell

-5.33%

Downside

Reiterated

12/11/25

Cautious Outlook for Fresenius Medical Care Amid Sector Challenges and Persistent Headwinds

Sam England

Berenberg Bank

€60

Buy

62.29%

Upside

Reiterated

12/03/25

Fresenius Medical Care AG & Co. KGaA (0H9X) Receives a Buy from Berenberg Bank

Hassan Al-Wakeel

Barclays

€51→€48

Hold

29.84%

Upside

Reiterated

11/24/25

Barclays Sticks to Their Hold Rating for Fresenius Medical Care AG & Co. KGaA (0H9X)

Richard Felton

Goldman Sachs

€60→€55

Buy

48.77%

Upside

Reiterated

11/07/25

Fresenius Medical Care AG & Co. KGaA (0H9X) Receives a Buy from Goldman Sachs

Unknown Analyst

DZ BANK AG

Not Ranked

DZ BANK AG

Buy

―

Reiterated

11/05/25

Falko Friedrichs

Deutsche Bank

€48

Hold

29.84%

Upside

Reiterated

11/05/25

Deutsche Bank Reaffirms Their Hold Rating on Fresenius Medical Care AG & Co. KGaA (0H9X)

James Vane

Jefferies

€36

Sell

-2.62%

Downside

Reiterated

11/04/25

Jefferies Keeps Their Sell Rating on Fresenius Medical Care AG & Co. KGaA (0H9X)

Lisa Bedell Clive

Bernstein

€54.5

Hold

47.42%

Upside

Reiterated

10/20/25

Bernstein Reaffirms Their Hold Rating on Fresenius Medical Care AG & Co. KGaA (0H9X)

Veronika Dubajova

Citi

€46.5→€52.5

Hold

42.01%

Upside

Reiterated

06/05/25

Fresenius Medical Care AG & Co. KGaA (0H9X) Receives a Hold from Citi

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Graham Doyle

UBS

Sell

―

Reiterated

01/14/26

UBS Reaffirms Their Sell Rating on Fresenius Medical Care AG & Co. KGaA (0H9X)

David Adlington

J.P. Morgan

€37.4

Sell

1.16%

Upside

Reiterated

01/14/26

J.P. Morgan Keeps Their Sell Rating on Fresenius Medical Care AG & Co. KGaA (0H9X)

Oliver Reinberg

Kepler Capital

€49

Hold

32.54%

Upside

Reiterated

01/13/26

Kepler Capital Sticks to Its Hold Rating for Fresenius Medical Care AG & Co. KGaA (0H9X)

Harald Hof

mwb research

€46→€47

Buy

27.13%

Upside

Upgraded

01/12/26

Aisyah Noor

Morgan Stanley

€39→€37

Sell

0.08%

Upside

Reiterated

12/15/25

Fresenius Medical price target lowered to EUR 37 from EUR 39 at Morgan StanleyFresenius Medical price target lowered to EUR 37 from EUR 39 at Morgan Stanley

Anna Ractliffe

Bank of America Securities

€38→€35

Sell

-5.33%

Downside

Reiterated

12/11/25

Cautious Outlook for Fresenius Medical Care Amid Sector Challenges and Persistent Headwinds

Sam England

Berenberg Bank

€60

Buy

62.29%

Upside

Reiterated

12/03/25

Fresenius Medical Care AG & Co. KGaA (0H9X) Receives a Buy from Berenberg Bank

Hassan Al-Wakeel

Barclays

€51→€48

Hold

29.84%

Upside

Reiterated

11/24/25

Barclays Sticks to Their Hold Rating for Fresenius Medical Care AG & Co. KGaA (0H9X)

Richard Felton

Goldman Sachs

€60→€55

Buy

48.77%

Upside

Reiterated

11/07/25

Fresenius Medical Care AG & Co. KGaA (0H9X) Receives a Buy from Goldman Sachs

Unknown Analyst

DZ BANK AG

Not Ranked

DZ BANK AG

Buy

―

Reiterated

11/05/25

Falko Friedrichs

Deutsche Bank

€48

Hold

29.84%

Upside

Reiterated

11/05/25

Deutsche Bank Reaffirms Their Hold Rating on Fresenius Medical Care AG & Co. KGaA (0H9X)

James Vane

Jefferies

€36

Sell

-2.62%

Downside

Reiterated

11/04/25

Jefferies Keeps Their Sell Rating on Fresenius Medical Care AG & Co. KGaA (0H9X)

Lisa Bedell Clive

Bernstein

€54.5

Hold

47.42%

Upside

Reiterated

10/20/25

Bernstein Reaffirms Their Hold Rating on Fresenius Medical Care AG & Co. KGaA (0H9X)

Veronika Dubajova

Citi

€46.5→€52.5

Hold

42.01%

Upside

Reiterated

06/05/25

Fresenius Medical Care AG & Co. KGaA (0H9X) Receives a Hold from Citi

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Fresenius Medical Care AG & Co. KGaA

3 Months

xxx

Success Rate

10/18 ratings generated profit

Average Return

+1.87%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +1.87% per trade.

1 Year

James VaneJefferies

Success Rate

27/47 ratings generated profit

Average Return

-2.73%

reiterated a sell rating 2 months ago

Copying James Vane's trades and holding each position for 1 Year would result in 57.45% of your transactions generating a profit, with an average return of -2.73% per trade.

2 Years

xxx

Success Rate

24/47 ratings generated profit

Average Return

-5.63%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 51.06% of your transactions generating a profit, with an average return of -5.63% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

FME Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, FME has received 4 Buy Ratings, 7 Hold Ratings, and 10 Sell Ratings. FME average Analyst price target in the past 3 months is 46.08.

Each month's total comprises the sum of three months' worth of ratings.

FME Financial Forecast

FME Earnings Forecast

Next quarter’s earnings estimate for FME is €1.03 with a range of €0.77 to €1.34. The previous quarter’s EPS was €1.10. FME beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year FME has Performed in-line its overall industry.

FME Sales Forecast

Next quarter’s sales forecast for FME is €4.81B with a range of €3.92B to €5.15B. The previous quarter’s sales results were €4.88B. FME beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year FME has Performed in-line its overall industry.

FME Stock Forecast FAQ

What is DE:FME’s average 12-month price target, according to analysts?

Based on analyst ratings, Fresenius Medical Care AG & Co. KGaA’s 12-month average price target is 46.08.

What is DE:FME’s upside potential, based on the analysts’ average price target?

Fresenius Medical Care AG & Co. KGaA has 24.64% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Fresenius Medical Care AG & Co. KGaA a Buy, Sell or Hold?

Fresenius Medical Care AG & Co. KGaA has a consensus rating of Hold, which is based on 4 buy ratings, 4 hold ratings and 5 sell ratings.

What is Fresenius Medical Care AG & Co. KGaA’s share price target?

The average share price target for Fresenius Medical Care AG & Co. KGaA is 46.08. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €60.00 ,and the lowest forecast is €35.00. The average share price target represents 24.64% Increase from the current price of €36.97.

What do analysts say about Fresenius Medical Care AG & Co. KGaA?

Fresenius Medical Care AG & Co. KGaA’s analyst rating consensus is a Hold. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of Fresenius Medical Care AG & Co. KGaA?

To buy shares of DE:FME, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Fresenius Medical Care AG & Co. KGaA (FME) Stock Forecast & Price Target

FME Analyst Ratings

FME Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Fresenius Medical Care AG & Co. KGaA

FME Analyst Recommendation Trends

FME Financial Forecast

FME Earnings Forecast

FME Sales Forecast

FME Stock Forecast FAQ

Detailed List of Analyst Forecasts